<DOC>
	<DOC>NCT00198497</DOC>
	<brief_summary>The purpose of this study is to determine if intravitreal injection of Vitrase (ovine hyaluronidase) clears vitreous hemorrhage</brief_summary>
	<brief_title>Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Vitreous Hemorrhage</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Severe vitreous hemorrhage that obscures visualization of the fundus on indirect ophthalmoscopy, that has been present &gt;/= 1 month by history or exam BCVA is worse than 20/200 at time of screening Corneal or lenticular abnormalities that preclude fundus observation Ongoing ocular infection, inflammation or history of herpetic corneal lesion Current or prior retinal detachment or retinal tears or breaks or intraocular tumor More than 1 severe vitreous hemorrhage within 6 months Previous vitrectomy for any reason Hemorrhage is exclusively preretinal, or old &amp; organized Prior Vitrase for intravitreal injection in either eye No light perception in either eye at any time Known contraindications to study medication Sickle cell disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>